AC Immune
Develops protein-misfolding therapies and diagnostics for neurodegenerative diseases.
Something off on this page? Send us feedback.
Profile
Uses its SupraAntigen and Morphomer platforms to develop therapeutics and diagnostics for neurodegenerative diseases tied to misfolded proteins. Proprietary clinical development is paired with pharmaceutical partnerships that provide non-dilutive funding.
Built around the SupraAntigen and Morphomer technology platforms, the Lausanne-based clinical-stage company develops therapeutic and diagnostic programs for neurodegenerative diseases associated with misfolded proteins. Its work includes active immunotherapies and selected small-molecule programs, targeting conditions including Alzheimer’s and Parkinson’s disease.
Proprietary development is paired with strategic pharmaceutical collaborations, including relationships with Takeda, Janssen, and Lilly. Those collaborations can advance parts of the pipeline and supply non-dilutive funding for proprietary programs.
Following a strategic review, the company narrowed its pipeline to selected clinical programs and operational priorities. It operates as a Swiss company from Lausanne while its common shares trade on Nasdaq under ACIU.
Company facts
Key statistics
Year to date −20.7% · Average volume (30d) 216.6K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Target |
|---|---|---|---|
| Mar 13, 2026 | Jefferies | Target | $7 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 5, 2026Q2 FY26 | −$0.10 | $0.03 | +128.7% | $9.6M | $9.8M | +2.6% | +0.88% |
| Apr 30, 2026Q1 FY26 | −$0.20 | −$0.19 | +5.0% | $329.4K | $1.4M | +325.0% | −1.65% |
| Mar 13, 2026Q4 FY25 | −$0.19 | −$0.18 | +5.3% | $1.4M | $428.9K | −70.3% | +3.64% |
| Nov 4, 2025Q3 FY25 | −$0.22 | −$0.20 | +9.1% | $1.1M | $1.2M | +3.2% | +3.94% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $1.2M | $1.6M | $1.2M | $417.7K | $1.4M | $18.7M | |
| Gross profit | $1.2M | $1.6M | $1.2M | $417.7K | $1.4M | $18.7M | |
| Operating income | −$23.9M | −$24.0M | −$20.0M | −$17.8M | −$18.3M | $1.5M | |
| Net income | −$23.5M | −$26.2M | −$19.6M | −$17.8M | −$18.3M | $2.3M | |
| Diluted EPS | −$0.23 | −$0.26 | −$0.20 | −$0.17 | −$0.19 | $0.02 | |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Operating margin | -1,956.6% | -1,484.5% | -1,721.6% | -4,262.1% | -1,321.5% | 7.9% |
Fiscal years (4-quarter sums)FY21 $0 · FY22 $4.9M · FY23 $18.3M · FY24 $33.8M · FY25 $4.4M
Balance sheet, Jun 30, 2026Cash & short-term investments $93.1M · Total debt $5.1M · Total assets $185.9M · Shareholders' equity $43.5M
Dividends
No dividends on record.
Ownership
Shares outstanding 101.77M · Float 62.57M · 61.5% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BVF Inc/IL | 19.82M | 19.48% | 13F | Aug 14, 2026 |
| Andrea Pfeifer · director, officer: Chief Executive Officer | 3.82M | 3.75% | Form 4 | May 18, 2026 |
| Wells Fargo & Company/MN | 1.00M | 0.99% | 13F | Aug 14, 2026 |
| Renaissance Technologies LLC | 840.1K | 0.83% | 13F | Aug 13, 2026 |
| Millennium Management LLC | 773.6K | 0.76% | 13F | Aug 14, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 15, 2026 | Andrea Pfeifer | director, officer: Chief Executive Officer | −10,000 | $2.79 |
| Apr 15, 2026 | Andrea Pfeifer | director, officer: Chief Executive Officer | +10,000 | $3.14 |
| Apr 15, 2026 | Andrea Pfeifer | director, officer: Chief Executive Officer | −10,000 | $3.14 |
Peers
- Eli Lilly
Tau PET and neuroinflammation programs in Alzheimer's and Parkinson's
- Lantheus
Registrational tau PET imaging program for Alzheimer's disease
- Teva (ADR)
Phase 2 alpha-synuclein therapy for multiple system atrophy
- Acumen Pharmaceuticals
Phase 2 amyloid-beta oligomer antibody for early Alzheimer's
- Prothena
Amyloid-, tau-, and alpha-synuclein programs in neurodegeneration
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| AC Immune | $2.65 | −0.56% | $269.7M | — | — | 12.5 | +498.6% |
| Eli Lilly | $1,173.00 | −0.08% | $1.10T | 39.4 | 28.7 | 13.9 | +47.7% |
| Lantheus | $100.51 | −0.24% | $6.56B | 24.3 | 18.3 | 4.2 | +2.7% |
| Teva (ADR) | $36.30 | −0.36% | $42.44B | 60.7 | 12.9 | 2.5 | −0.8% |
| Acumen Pharmaceuticals | $2.92 | +0.17% | $210.9M | — | — | — | — |
| Prothena | $9.33 | 0.00% | $488.5M | — | — | 9.0 | −77.2% |
| Median | 39.4 | 18.3 | 6.6 | +0.9% |